Company profile

GlycoEra AG

GlycoEra AG is a biotechnology company building a high-value pipeline of medicines based on deep expertise in glycobiology and protein degradation. GlycoEras innovative CustomGlycan platform enables the design, engineering, and development of novel biologics for a broad range of indications. GlycoEra is advancing a range of assets toward human clinical studies.

Source: startup.ch

Highlights

Top 100 Swiss Startup Award 2023

Top 100 Swiss Startup Award 2022

More news about GlycoEra AG

08.01.2024 11:50

Bristol Myers Squibb invests in GlycoEra

Financing

12.05.2023 14:20

Startups welcome seasoned industry leaders to their board

Support

27.07.2022 09:00

Startups rely on seasoned board members’ expertise

Support

09.05.2022 08:50

C-Level managers for tech startups

Expansion

12.11.2021 10:00

GlycoEra seals series A financing round at CHF 45 million

Financing

19.01.2021 09:38

LimmaTech launches spin-out for drug development

Launch

Founded
2020

Kanton
Zürich

Homepage

Principal

Swiss Venture Capital Report

The new Swiss Venture Capital Report provides a review of the whole of 2023. In addition to investments, the report will once again include the results of a survey of Swiss investors, an overview of venture capital fundraising and a list of exits. You can download the Report in our asset section.